Providers say scalp micropigmentation suits most skin types and describe patch tests, hypoallergenic pigments and a skin consultation for sensitive skin. These are provider claims rather than independent safety evidence, and pigment reactions remain a risk.
Minoxidil is FDA-approved for scalp hair loss and backed by decades of large trials; bimatoprost is approved only for eyelashes, and the published scalp evidence is limited to small short studies, so on the scalp it is off-label and experimental.
Scalp micropigmentation offers a non-invasive, low-maintenance, and immediate hair loss solution.
No published trial has tested melatonin together with minoxidil or Redensyl, and no interaction study exists — so the combination is untested rather than shown to be safe. The melatonin scalp evidence on its own is one small placebo-controlled trial plus several uncontrolled studies.
Providers describe scalp micropigmentation as low-risk when a trained practitioner uses sterile single-use equipment, but that is a provider claim rather than a regulatory finding: pigment allergy, infection and colour change are documented risks of cosmetic tattooing.
Alopecia areata is an autoimmune condition, and salicylic acid does not promote hair regrowth.
Good candidates for scalp micropigmentation include anyone experiencing hair loss or thinning.
Scalp Micropigmentation creates the illusion of hair follicles on the scalp for visible hair loss.
Melatonin may cause hair loss or thinning in some users, but evidence is limited.
Mild local effects like dryness and itching may occur with long-term use.
Use baricitinib only with a medical diagnosis of alopecia areata.
Scalp micropigmentation does not cause hair loss and is a cosmetic treatment.
Baricitinib helps regrow hair by targeting the autoimmune response in alopecia areata.
Scalp micropigmentation can effectively enhance the appearance of a receding hairline.
Scalp micropigmentation does not grow hair back; it only enhances appearance.
Many providers offer flexible financing options and third-party payment plans for scalp micropigmentation.
Fluocinolone is a prescription topical corticosteroid used for inflammatory scalp conditions such as seborrheic dermatitis, scalp psoriasis and scarring alopecias. It calms inflammation rather than growing hair, it is not a treatment for pattern hair loss, and its labelling warns against prolonged use.
Verteporfin is being studied for hair follicle regeneration due to its ability to inhibit YAP, promoting tissue healing.
Verteporfin is an intravenous drug approved only for an eye condition; it is not approved for hair loss in any form. In the few published hair reports it was injected into the scalp alongside surgical wounding — unverified case reports of one and two patients, not trial evidence.
Published studies link tofacitinib mainly to alopecia areata and its severe variants — as an off-label drug being studied for them, not as a cause of hair loss. The evidence is mostly small, open-label or retrospective, and relapse after stopping is commonly reported.
GT20029 is not approved or commercially available anywhere and remains investigational. A published 12-week Phase II study in 180 Chinese men reports hair-count gains over placebo, but no long-term or Phase III data exists, so any launch is years away at best.
Oral tofacitinib acts on immune signalling throughout the body and has the stronger regrowth evidence in alopecia areata, alongside an FDA boxed warning; topical tofacitinib aims to act only on the scalp, but the human evidence is a handful of small compounded-formulation studies with no large randomized trial. Neither route is approved for hair loss, and regrowth generally reverses after treatment stops.
Tofacitinib is a prescription JAK inhibitor approved for rheumatoid arthritis, psoriatic arthritis and ulcerative colitis — not for alopecia areata. It is discussed for hair loss because a 2014 case report and a 2016 open-label trial reported regrowth in severe alopecia areata, but that use is off-label, the regrowth relapsed after stopping, and the drug carries an FDA boxed warning.
Procapil is a cosmetic ingredient complex; laboratory studies of its individual ingredients report anti-inflammatory effects, but no published clinical trial has tested it in alopecia areata or any other immune-related hair loss. Spreading bald patches should be assessed by a dermatologist.
Scalp micropigmentation is generally suitable for various types of hair loss.
Providers describe SMP pigments as safe, medical-grade and made for the scalp, but those are supplier and clinic descriptions rather than regulatory approvals: no colour additive is approved for injection into the skin, and allergic reactions to tattoo pigment are documented.
Common side effects may include scalp irritation, redness, or itching.
Scalp micropigmentation is generally cheaper than a hair transplant.
The two are not interchangeable and the evidence points the other way from the common assumption: topical selenium disulfide shampoo has clinical trial support for dandruff and seborrheic dermatitis, while oral selenium supplements have no reliable evidence for hair growth in people who are not deficient, and excess intake is a recognised cause of hair loss.
Tofacitinib is a medical treatment because it targets underlying immune conditions affecting hair growth.